Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Maralixibat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 known ✓ | Q12908 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maralixibat SCHEMBL10013954 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| Maralixibat SCHEMBL6336189 | 0.99 | SLC10A2 (1.00) | SLC10A2 | |
| Maralixibat SCHEMBL2564753 | 0.99 | SLC10A2 (1.00) | SLC10A2 | |
| Maralixibat SCHEMBL2564749 | 0.99 | SLC10A2 (1.00) | SLC10A2 | |
| Maralixibat SCHEMBL6336186 | 0.99 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL27193090 | 0.98 | SLC10A2 (0.96) | SLC10A2 | |
| SCHEMBL27193088 | 0.93 | SLC10A2 (0.87) | SLC10A2 | |
| SCHEMBL27206765 | 0.92 | SLC10A2 (0.85) | SLC10A2 | |
| Hydrochloric Acid SCHEMBL27206760 | 0.91 | SLC10A2 (0.84) | SLC10A2 | |
| Hydrochloric Acid SCHEMBL6336188 | 0.91 | SLC10A2 (0.85) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4587428-A1 | MARALIXIBAT SOLID FORMS, INTERMEDIATES AND PROCESSES OF MAKING SAME | Mirum Pharmaceuticals, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20240116891-A1 | MARALIXIBAT SOLID FORMS, INTERMEDIATES AND PROCESSES OF MAKING SAME | MIRUM PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| WO-2024059163-A1 | MARALIXIBAT SOLID FORMS, INTERMEDIATES AND PROCESSES OF MAKING SAME | MIRUM PHARMACEUTICALS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20230302012-A1 | Treating Progressive Familial Intrahepatic Cholestasis (PFIC) with IBAT Inhibitors | ALBIREO AB (SE) | 2023-09-28 | — | — | US | disclosed |
| US-20160310518-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | LUMENA PHARMACEUTICALS LLC (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302012-A1 | Treating Progressive Familial Intrahepatic Cholestasis (PFIC) with IBAT Inhibitors | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885 |
| US-20240116891-A1 | MARALIXIBAT SOLID FORMS, INTERMEDIATES AND PROCESSES OF MAKING SAME | MPST, SULT2A1, CYP2B6 | SLC10A2 316/4885 |
| US-20160310518-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.